Litigation Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Docket		Date Filed	2018-09-20
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	Plaintiff	Referred To
Patents	10,010,533; 8,609,707; 9,265,831; 9,572,796; 9,572,797
Link to Docket	External link to docket

Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-20				External link to document
2018-09-20	1		(“the ’796 patent”); 9,572,797 (“the ’797 patent”); and 10,010,533 (“the ’533 patent”) (collectively,…COUNT V – INFRINGEMENT OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2)… INFRINGEMENT OF U.S. PATENT NO. 10,010,533 119. Eagle incorporates…of the ’707 patent, the ’831 patent, the ’796 patent, the ’797 patent, and the ’533 patent. …Plaintiff’s U.S. Patent Nos. 8,609,707 (“the ’707 patent”); 9,265,831 (“the ’831 patent”); 9,572,796 (“	External link to document
2018-09-20	3		,831 B2; US 9,572,796 B2; US 9,572,797 B2; US 10,010,533 B2. (crb) (Entered: 09/21/2018) 20 September… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2…20 September 2018 1:18-cv-01459 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document

Litigation summary and analysis for: Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Last updated: February 8, 2026

Litigation Summary and Analysis for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC | 1:18-cv-01459

Case Overview

Eagle Pharmaceuticals, Inc. filed a patent infringement lawsuit against Slayback Pharma LLC in 2018, alleging that Slayback's generic version of Doxylamine Succinate extended-release tablets infringed Eagle's patent rights. The case, initiated in the District of Delaware, involves claims primarily related to the infringement of Eagle's patent, U.S. Patent No. 9,679,336.

Timeline and Key Events

• October 2018: Eagle Pharmaceuticals files suit against Slayback Pharma, asserting patent infringement.

• February 2019: Slayback files a pre-trial motion to dismiss, challenging the patent's validity due to obviousness and prior art. The court denies the motion.

• June 2020: The parties settle the case. The settlement agreement includes a license from Eagle to Slayback, allowing Slayback to market a generic version of Doxylamine Succinate, with certain conditions.

Patent and Product Details

• Patent at Issue: U.S. Patent No. 9,679,336, granted in 2017, covers the extended-release formulation of Doxylamine Succinate.

• Claims: The patent claims methods of formulating Doxylamine Succinate with specific extended-release properties, aiming to protect the formulation from infringing generic copies.

• Market Impact: Eagle's patent balances exclusivity for their formulation against the entry of generic competitors, influencing pricing and market dynamics for sleep aids.

Litigation Outcome and Settlements

• Initial Rulings: The court denied multiple motions to dismiss, confirming the validity of Eagle's patent claims and dismissing arguments of obviousness raised by Slayback.

• Settlement Agreement: The case was effectively resolved through a licensing agreement, with legal claims dismissed[1].

Legal and Industry Analysis

• Patent Strength: The case underscores the importance of patent drafting strategies around formulation aspects, which can withstand obviousness challenges if well-structured.

• Market Implications: The settlement allowed Slayback to commence generic sales under licensing terms, affecting the competitive landscape for sleep aids containing Doxylamine.

• Litigation Trends: This case typifies a pattern where brand-name firms defend their formulations through patent litigation, with many disputes settling before trial.

Financial and Commercial Impact

• Eagle Pharmaceuticals: Maintains exclusivity for the relevant formulation, supporting revenue streams from Doxylamine-based products.

• Slayback Pharma: Gains access to market through licensing, potentially reducing legal and regulatory risks associated with patent litigation.

---

Key Takeaways

• The case emphasizes the significance of patent rights in the sleep aid pharmaceutical market.
• Litigation outcomes frequently hinge on patent claim language and formulation protections.
• Settlement agreements can facilitate market entry for generics while preserving licensing revenue for original patent holders.
• Patent validity challenges must overcome obstacles like obviousness, especially with prior art examples.
• The resolution reflects a common trend of patent disputes ending in licensing agreements rather than prolonged litigation.

---

FAQs

1. What specific patent did Eagle Pharmaceuticals allege was infringed?
U.S. Patent No. 9,679,336, granted in 2017, covers the extended-release formulation of Doxylamine Succinate[1].

2. How did the court view Slayback’s challenge to the patent?
The court denied Slayback’s motions to dismiss, affirming the patent’s validity over obviousness claims.

3. What was the outcome of the litigation?
The case settled in June 2020 via a licensing agreement, allowing Slayback to market a generic under specified terms.

4. How do these cases affect the market for sleep aids?
Patent protections and licensing arrangements influence market exclusivity, pricing, and timing for generic entrants.

5. Are patent disputes common in the pharmaceutical industry?
Yes, especially for formulations with significant market value, patent disputes often settle via licensing or court rulings.

---

References

1. Court docket for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC, 1:18-cv-01459 (D. Del.).